The Emerging Role of lncRNAs in Cancer Therapy DOI Creative Commons
Naveed Shuja

Developmental medico-life-sciences, Journal Year: 2024, Volume and Issue: 1(9), P. 1 - 3

Published: Dec. 18, 2024

In recent decades, cancer biology has witnessed unprecedented advances in the study of biology, and long noncoding RNAs (lncRNAs) are now known to play central roles progression, regulation, therapeutic response[1]. Since their discovery, lncRNAs have been quickly becoming focus oncology research, given critical gene expression tumor microenvironment therapy resistance, once thought as transcriptional noise. These discoveries hold promise for developing novel diagnostic biomarkers well targeted therapies, furthering field precision oncology[2]. Types lncRNAs: LncRNAs can be grouped according location genome, structure, mode action. The major types include: Intergenic (lincRNAs): They transcribed from regions between protein-coding genes do not require regulation adjacent genes[3]. Intronic originate introns either regulate host or independent. Sense transcribe same strand region genes, but code nothing[4]. Antisense opposite through complementary base-pairing. Enhancer (eRNAs): were enhancer act enhance transcription nearby genes. Circular (circRNAs): CircRNAs highly stable formed by back-splicing events, competing with miRNAs binding regulating This classification underscores structural complexity versatility diversity lncRNAs[3]. Functional Complexity class comprises diverse that longer than 200 nucleotides. As a result, they show exquisite at multiple levels, including epigenetic, transcriptional, post-transcriptional, interactions DNA, RNA, proteins. ability functionally plasticity allows them orchestrate key biological processes such proliferation, apoptosis, metastasis, angiogenesis, immune evasion[5]. Importantly, dysregulated several cancers lung, breast, colorectal, head neck squamous cell carcinoma (HNSCC), making oncogenes suppressors. last few years also revealed may modulate signaling pathways PI3K/AKT, Wnt/β-catenin, p53, NF-κB influence survival, drug directly. For example, lncRNA MALAT1 HOTAIR well-established oncogenic associated metastasis poor prognosis, while MEG3 GAS5 suppressor induce apoptosis inhibit proliferation. intricate context-specific functions progression underscored this dual nature[6]. Therapy Resistance LncRNAs: resistance is one impediments treatment, frequently resulting disease recurrence patient outcomes. More more evidence showing mediators chemotherapy, radiotherapy, therapies. mechanisms include epithelial-mesenchymal transition (EMT), autophagy efflux pump modulation, inhibition[7]. an H19 shown confer tyrosine kinase inhibitors (TKIs) lung upregulating enzyme glycolysis, PKM2. Like UCA1 PVT1, promote cisplatin sponging suppressive activating pro-survival pathways. If we target these resistance-associated lncRNAs, sensitize cells improve effectiveness[8]. Biomarkers Therapeutic Targets: unique profiles high tissue specificity, thus promising candidates biomarkers. Detection fluids possible provide minimally invasive prognostic tools. There already PCA3 (prostate cancer) HULC (hepatocellular carcinoma) potential used markers clinical translation[9]. addition, new strategy targeting lncRNAs. Silencing restoration performed technologies RNA interference (RNAi), antisense oligonucleotides (ASO), CRISPR/Cas systems. stability bioavailability therapeutics further enhanced nanoparticle-based delivery systems hope successful practice[10]. Future Perspectives Challenges: Despite promise, there still challenges overcome Current context-dependent understood, no effective system exists facilitate application. personalized approaches lncRNA-based therapies needed heterogeneity cancer[11]. research should unweave molecular cancer, identify reliable response, explore drugs. To bring patients, collaborative efforts combine multi-omics technologies, artificial intelligence, trials will critical[12, 13]. CONCLUSION emerging agent, adding paradigm biology. regulators tumorigenesis, great diagnosis, treatment. advance day transform patients fighting formidable disease.

Language: Английский

Connecting the Dots: LncRNAs in the KRAS Pathway and Cancer DOI
Mudasir Maqbool, Md Sadique Hussain, Ajay Singh Bisht

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 262, P. 155570 - 155570

Published: Aug. 29, 2024

Language: Английский

Citations

10
Recognition of Cyber Physical Systems Through Network Security for Wireless Sensor Networks DOI

S. Selvakanmani,

S. Kaliappan,

M. Muthukannan

et al.

Advances in computer and electrical engineering book series, Journal Year: 2024, Volume and Issue: unknown, P. 272 - 286

Published: March 15, 2024

This chapter presents a novel approach for recognizing and securing cyber-physical systems (CPS) through the use of artificial intelligence in wireless sensor networks. The increasing CPS various fields has led to growing need effective methods identifying these systems. proposed utilizes techniques analyse network traffic identify patterns that indicate presence CPS. Additionally, uses this information secure by implementing appropriate security measures protect against cyber-attacks. study highlights importance networks, potential meet need. It also emphasizes developing resilient face cyber-threats holistic

Language: Английский

Citations

0
Efficient Design and Optimization of High-Speed Electronic System Interconnects Using Machine Learning Applications DOI
A. Saravanan,

S. Bathrinath,

Hari Banda

et al.

Advances in systems analysis, software engineering, and high performance computing book series, Journal Year: 2024, Volume and Issue: unknown, P. 254 - 273

Published: June 28, 2024

This work presents a holistic framework for automating automated guided vehicles (AGVs) in industrial settings by using well-positioned sensors and sophisticated machine learning models. The AGV is put through rigorous testing along variety of pathways. It outfitted with such as wheel encoders, proximity sensors, ultrasonic LIDAR. Microcontrollers the high-speed electronic system enable real-time data processing decision-making based on sensor inputs. For purpose anticipating impediments maximising routes, models decision trees (DT), artificial neural networks (ANN), support vector machines (SVM), random forests (RF) are developed assessed. Experiments showing accuracy, F1 score, precision, recall show how well integrated is. prime example effective route planning, obstacle avoidance, navigation busy settings.

Language: Английский

Citations

0
Lightning Impact Current Variables in Wearable and Implantable Devices on Different Evaluation Methods DOI
L. Natrayan, M. Saravanan,

V. Paranthaman

et al.

Advances in chemical and materials engineering book series, Journal Year: 2024, Volume and Issue: unknown, P. 383 - 397

Published: May 31, 2024

This work introduces a novel and expedient method to evaluate the impact of lightning-induced current variables on wearable implantable devices. The focuses analyzing waveform parameters lightning intensity modulation, crucial factor in assessing vulnerability these devices strikes. Key properties such as maximum voltage (Up), frontal duration (T1), time half (T2), overrun frequency (Be) are evaluated following IEC specifications. To accurately determine parameters, an optimization technique employing rear supervised learning is applied. analyzes baseline curvature its variations using data collected from 14 distinct points along waveforms, particularly focusing 26% signal applied wave's front portion 50% open-circuit portion. prescribed 28 waveforms incorporated into network subject's training process, multiple experimental cases employed validate proposed method.

Language: Английский

Citations

0
The Emerging Role of lncRNAs in Cancer Therapy DOI Creative Commons
Naveed Shuja

Developmental medico-life-sciences, Journal Year: 2024, Volume and Issue: 1(9), P. 1 - 3

Published: Dec. 18, 2024

In recent decades, cancer biology has witnessed unprecedented advances in the study of biology, and long noncoding RNAs (lncRNAs) are now known to play central roles progression, regulation, therapeutic response[1]. Since their discovery, lncRNAs have been quickly becoming focus oncology research, given critical gene expression tumor microenvironment therapy resistance, once thought as transcriptional noise. These discoveries hold promise for developing novel diagnostic biomarkers well targeted therapies, furthering field precision oncology[2]. Types lncRNAs: LncRNAs can be grouped according location genome, structure, mode action. The major types include: Intergenic (lincRNAs): They transcribed from regions between protein-coding genes do not require regulation adjacent genes[3]. Intronic originate introns either regulate host or independent. Sense transcribe same strand region genes, but code nothing[4]. Antisense opposite through complementary base-pairing. Enhancer (eRNAs): were enhancer act enhance transcription nearby genes. Circular (circRNAs): CircRNAs highly stable formed by back-splicing events, competing with miRNAs binding regulating This classification underscores structural complexity versatility diversity lncRNAs[3]. Functional Complexity class comprises diverse that longer than 200 nucleotides. As a result, they show exquisite at multiple levels, including epigenetic, transcriptional, post-transcriptional, interactions DNA, RNA, proteins. ability functionally plasticity allows them orchestrate key biological processes such proliferation, apoptosis, metastasis, angiogenesis, immune evasion[5]. Importantly, dysregulated several cancers lung, breast, colorectal, head neck squamous cell carcinoma (HNSCC), making oncogenes suppressors. last few years also revealed may modulate signaling pathways PI3K/AKT, Wnt/β-catenin, p53, NF-κB influence survival, drug directly. For example, lncRNA MALAT1 HOTAIR well-established oncogenic associated metastasis poor prognosis, while MEG3 GAS5 suppressor induce apoptosis inhibit proliferation. intricate context-specific functions progression underscored this dual nature[6]. Therapy Resistance LncRNAs: resistance is one impediments treatment, frequently resulting disease recurrence patient outcomes. More more evidence showing mediators chemotherapy, radiotherapy, therapies. mechanisms include epithelial-mesenchymal transition (EMT), autophagy efflux pump modulation, inhibition[7]. an H19 shown confer tyrosine kinase inhibitors (TKIs) lung upregulating enzyme glycolysis, PKM2. Like UCA1 PVT1, promote cisplatin sponging suppressive activating pro-survival pathways. If we target these resistance-associated lncRNAs, sensitize cells improve effectiveness[8]. Biomarkers Therapeutic Targets: unique profiles high tissue specificity, thus promising candidates biomarkers. Detection fluids possible provide minimally invasive prognostic tools. There already PCA3 (prostate cancer) HULC (hepatocellular carcinoma) potential used markers clinical translation[9]. addition, new strategy targeting lncRNAs. Silencing restoration performed technologies RNA interference (RNAi), antisense oligonucleotides (ASO), CRISPR/Cas systems. stability bioavailability therapeutics further enhanced nanoparticle-based delivery systems hope successful practice[10]. Future Perspectives Challenges: Despite promise, there still challenges overcome Current context-dependent understood, no effective system exists facilitate application. personalized approaches lncRNA-based therapies needed heterogeneity cancer[11]. research should unweave molecular cancer, identify reliable response, explore drugs. To bring patients, collaborative efforts combine multi-omics technologies, artificial intelligence, trials will critical[12, 13]. CONCLUSION emerging agent, adding paradigm biology. regulators tumorigenesis, great diagnosis, treatment. advance day transform patients fighting formidable disease.

Language: Английский

Citations

0